[{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"6fa58343-5f41-4e65-b9b7-ed2e1d17361f","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06116682","created_at":"2023-11-03T20:12:32.614Z","updated_at":"2025-02-25T14:10:16.796Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06116682 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/19/2024","start_date":" 11/19/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-19"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"917b48fd-6760-442b-9dca-351ad6f6d491","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299141","created_at":"2021-01-17T17:53:09.705Z","updated_at":"2025-02-25T15:33:17.802Z","phase":"Phase 2","brief_title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02299141","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • ALK • TP53 • FLT1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • RET rearrangement","tags":["EGFR • ALK • TP53 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2015","start_date":" 05/07/2015","primary_txt":" Primary completion: 01/09/2020","primary_completion_date":" 01/09/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-11"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"a58385e3-f746-48dd-bf8f-10d8e83d28bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01708954","created_at":"2021-01-18T07:26:37.698Z","updated_at":"2025-02-25T16:36:12.668Z","phase":"Phase 2","brief_title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01708954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • RET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion","tags":["HER-2 • KRAS • BRAF • RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 02/13/2013","start_date":" 02/13/2013","primary_txt":" Primary completion: 08/14/2015","primary_completion_date":" 08/14/2015","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"74a856b5-259a-4d5c-9166-0007d61a1cb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05570825","created_at":"2022-10-07T15:08:08.992Z","updated_at":"2024-07-02T16:35:05.631Z","phase":"Phase 2","brief_title":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05570825","lead_sponsor":"University of Washington","biomarkers":" PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-07"},{"id":"592ebddd-dcd6-4b4f-ad61-a8f732fba350","acronym":"ARROW","url":"https://clinicaltrials.gov/study/NCT03037385","created_at":"2021-01-17T17:13:27.011Z","updated_at":"2024-07-02T16:35:10.042Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","source_id_and_acronym":"NCT03037385 - ARROW","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 589","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 03/21/2024","primary_completion_date":" 03/21/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-11"},{"id":"11e80090-69af-4a10-8567-99e826b98c88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949606","created_at":"2023-07-20T15:09:17.002Z","updated_at":"2024-07-02T16:35:27.645Z","phase":"Phase 1/2","brief_title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05949606","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e izalontamab (SI-B001) • danvilostomig (SI-B003)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-11-29"},{"id":"c7e9b9c9-d4ce-4d93-91cb-690df0a318f7","acronym":"Delivir","url":"https://clinicaltrials.gov/study/NCT05788926","created_at":"2023-03-29T14:03:17.793Z","updated_at":"2024-07-02T16:35:32.334Z","phase":"Phase 1","brief_title":"A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)","source_id_and_acronym":"NCT05788926 - Delivir","lead_sponsor":"Transgene","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12","tags":["EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TG6050"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-10-20"},{"id":"7eec8313-ce6d-47bc-92b7-e0a3b9ab9f7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468985","created_at":"2021-01-18T17:05:50.225Z","updated_at":"2024-07-02T16:35:33.350Z","phase":"Phase 2","brief_title":"Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03468985","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative","tags":["EGFR • PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 05/09/2022","primary_completion_date":" 05/09/2022","study_txt":" Completion: 12/21/2022","study_completion_date":" 12/21/2022","last_update_posted":"2023-10-17"},{"id":"a368028e-686f-48d5-a817-2e4343d80bdf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712877","created_at":"2021-01-19T20:52:47.325Z","updated_at":"2024-07-02T16:35:37.428Z","phase":"","brief_title":"Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers","source_id_and_acronym":"NCT04712877","lead_sponsor":"Lung Cancer Mutation Consortium","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2023-09-12"},{"id":"b9d29ac1-22f0-48b2-a031-d017175875c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914116","created_at":"2023-06-22T19:11:45.274Z","updated_at":"2024-07-02T16:35:37.381Z","phase":"Phase 1/2","brief_title":"A Study of DB-1311 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05914116","lead_sponsor":"DualityBio Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT324"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-09-12"},{"id":"8aea6752-9081-4156-8036-1fa904135caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05935774","created_at":"2023-07-07T14:09:36.968Z","updated_at":"2024-07-02T16:35:38.985Z","phase":"Phase 2","brief_title":"OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05935774","lead_sponsor":"University of Washington","biomarkers":" HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK","pipe":" | ","alterations":" BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion","tags":["HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • trabedersen (OT-101)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2028","study_completion_date":" 07/31/2028","last_update_posted":"2023-08-25"},{"id":"c81fb89a-a657-47dd-9b13-7d83c2b9a7e0","acronym":"APT-CUBE","url":"https://clinicaltrials.gov/study/NCT05473156","created_at":"2022-07-25T20:54:40.231Z","updated_at":"2024-07-02T16:35:56.496Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","source_id_and_acronym":"NCT05473156 - APT-CUBE","lead_sponsor":"AP Biosciences Inc.","biomarkers":" BRAF • MET • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation","tags":["BRAF • MET • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AP203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-02-03"},{"id":"03adee65-6ca4-4214-9895-a400ae19de0d","acronym":"LIBIL","url":"https://clinicaltrials.gov/study/NCT02511288","created_at":"2021-01-17T17:11:06.748Z","updated_at":"2024-07-02T16:36:23.287Z","phase":"","brief_title":"LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02511288 - LIBIL","lead_sponsor":"Centre Leon Berard","biomarkers":" HER-2 • PD-L1 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 mutation • MET amplification • RET rearrangement • ALK translocation","tags":["HER-2 • PD-L1 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 mutation • MET amplification • RET rearrangement • ALK translocation"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2021-10-08"},{"id":"04f417f0-1ac3-4430-8015-ad658e26c61d","acronym":"CRETA","url":"https://clinicaltrials.gov/study/NCT04131543","created_at":"2021-01-18T20:10:51.919Z","updated_at":"2024-07-02T16:36:54.463Z","phase":"Phase 2","brief_title":"Phase II Study With Cabozantinib in Patients With RET Positive NSCLC","source_id_and_acronym":"NCT04131543 - CRETA","lead_sponsor":"University of Bologna","biomarkers":" RET","pipe":" | ","alterations":" RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Unknown status","enrollment":" Enrollment 25","initiation":"Initiation: 08/07/2019","start_date":" 08/07/2019","primary_txt":" Primary completion: 08/07/2020","primary_completion_date":" 08/07/2020","study_txt":" Completion: 08/07/2022","study_completion_date":" 08/07/2022","last_update_posted":"2019-10-18"},{"id":"264c60af-4345-4c46-8c50-850a6db5099d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01829217","created_at":"2021-01-18T08:07:55.000Z","updated_at":"2024-07-02T16:37:05.673Z","phase":"Phase 2","brief_title":"Sunitinib in Never-Smokers With Lung Adenocarcinoma","source_id_and_acronym":"NCT01829217","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • ALK mutation • RET rearrangement","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • ALK mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2018-10-31"},{"id":"4a5136c2-1773-4888-b588-e2572a56c2fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01502410","created_at":"2021-01-18T06:18:19.480Z","updated_at":"2024-07-02T16:37:09.540Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer","source_id_and_acronym":"NCT01502410","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET • KDR • VEGFA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • RET mutation • RET rearrangement","tags":["RET • KDR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2018-06-26"}]